First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Merit Medical Systems: the story is balanced — US interventional procedure volumes - particularly cardiac catheterizations, peripheral vascular interventions…
★ Analysts see FY2026 revenue reaching $1.6B — +6.9% growth in a single year.
What Moves the Stock
1US interventional procedure volumes - particularly cardiac catheterizations, peripheral vascular interventions, and interventional oncology procedures which drive device utilization
2New product launch momentum and market share gains in embolization (competing with Boston Scientific, Terumo) and hemostasis (competing with Teleflex, Terumo)
3Gross margin trajectory driven by manufacturing efficiency, product mix shift toward higher-margin embolization/oncology devices, and raw material cost inflation
4International revenue growth, particularly in Europe and Asia-Pacific where distributor partnerships and direct expansion drive penetration
5M&A activity - Merit has historically grown through tuck-in acquisitions of complementary device portfolios
6Cardiovascular segment (~55-60% of revenue): angiography kits, catheters, guidewires, hemostasis products for cardiac catheterization labs
value - Stock trades at 2.8x P/S and 14.4x EV/EBITDA, below historical medtech averages…
Rising rates have modest negative impact through two channels: (1) higher borrowing costs on $250M+ debt balance (mix of fixed/variable)…
Watch on earnings: US hospital admissions and cardiac catheterization lab volumes (proxy for cardiovascular device demand), Medicare reimbursement rate changes for interventional cardiology and radiology procedures, Raw material cost inflation for polymers, metals, and specialty materials used in device manufacturing.
One Sentence Summary:
Merit Medical Systems: the story is balanced — us interventional procedure volumes - particularly cardiac catheterizations, peripheral vascular interventions.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.